The research aims to address the challenges in data quality and its impact on precision oncology trials in low- and middle-income countries (LMICs).
Assessment of existing data quality issues in LMICs
Evaluation of the impact of reclassification on patient eligibility
Analysis of genotype-guided trial processes
Improved data reclassification increases patient inclusion in trials
Enhanced access to DDR-targeting therapies for more patients in LMICs
Identification of critical gaps in current data management practices
Resumen
reclassification provides a rationale to include these patients in genotype-guided precision oncology trials, potentially expanding eligibility for DDR-targeting therapies.